Arcutis’s Phase III AD Win Bodes Well For Soon-To-Report Second Study
One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.
One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.